Abstract
The translocator protein (TSPO) is a mitochondrial outer membrane protein enriched in lipid-metabolic tissues, including white adipose tissue (WAT), but its physiological role in adipocytes remains poorly defined. Building on prior work that demonstrated a role for TSPO in mitochondrial fatty acid oxidation, we investigated whether TSPO contributes to adipocyte lipid homeostasis under metabolic stress. We employed a combination of in vivo and in vitro approaches using global Tspo knockout (Tspo−/−) mice, primary adipocyte cultures, and pharmacological TSPO-binding drugs to examine TSPO function. Our findings show that Tspo−/− mice exhibited increased gonadal and inguinal WAT mass and adipocyte hypertrophy following high-fat diet feeding in both sexes, with a modest late body weight increase in females, but no differences in feed intake. These changes were accompanied by suppression of key lipolytic genes, reduced circulating NEFA and glycerol levels, and altered expression of fatty acid oxidation genes. Lipidomic profiling showed no genotype-dependent changes, indicating impaired mobilization rather than altered lipid composition. In vitro, primary adipocytes derived from inguinal WAT of Tspo−/− mice exhibited enhanced lipid accumulation during differentiation and reduced expression of lipolytic genes. TSPO-binding drugs phenocopied this response in TSPO-expressing cells. Mechanistically, we identify protoporphyrin IX (PPIX), an endogenous TSPO ligand, as a suppressor of adipogenic and lipolytic programs. PPIX levels increase during adipogenesis, and its accrual inhibits both lipid accumulation and lipolytic programs. Our findings identify TSPO as a regulator of adipocyte lipid metabolism through a previously unrecognized TSPO-PPIX axis that influences lipid mobilization. This mechanism provides new insight into TSPO’s role in adipose metabolic adaptation.
Keywords: adipogenesis, triglyceride, fat, lipolysis, mitochondria
Introduction
The translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR), is an evolutionarily conserved 18 kDa protein embedded in the outer mitochondrial membrane (OMM) (1, 2). Initially discovered in steroidogenic tissues based on its binding affinity for benzodiazepine-like ligands, TSPO was proposed to facilitate mitochondrial cholesterol import – a critical, rate-limiting step in steroid hormone biosynthesis (3, 4). This model was supported by its OMM localization and the presence of a putative cholesterol recognition/interaction amino acid consensus (CRAC) motif (2, 5). However, definitive genetic ablation studies have since unequivocally demonstrated that TSPO is dispensable for steroidogenesis in mammals (6, 7, 8), with mitochondrial cholesterol import now solely attributed to the intermembrane space shuttle function of the steroidogenic acute regulatory protein (STAR) (9). Separately, TSPO was also found to associate with components of the mitochondrial permeability transition pore (MPTP), leading to a functional model linking TSPO to regulation of reactive oxygen species (ROS) production and apoptosis (10); however, this model has similarly been disproven (11). These findings have necessitated a major reassessment of TSPO’s biological role, positioning it as a central subject of renewed investigation in mitochondrial physiology (12, 13, 14).
TSPO remains of considerable biomedical interest due to its altered expression across a wide range of pathological conditions, including cancer, neurodegenerative diseases, inflammation, and metabolic dysfunction (15, 16, 17, 18). Notably, TSPO-targeted positron emission tomography (PET) imaging is widely employed to infer neuroinflammation (19, 20), further emphasizing its perceived involvement in cellular stress responses and mitochondrial signaling. Recent studies have proposed that TSPO may contribute to mitochondrial quality control, regulation of reactive oxygen species (ROS) production (21), apoptosis (22), and cellular bioenergetics (23), although these models remain mechanistically unresolved and sometimes contradictory.
Previous work from our laboratory (24) and emerging transcriptomic and proteomic datasets (25) reveal that TSPO is highly expressed not only in classical lipid-rich steroidogenic organs/tissues (26) but also in other metabolically active tissues, particularly white adipose tissue (18). In rodents, adipose TSPO expression appears to be modulated by metabolic status, including diet-induced obesity, thermogenic stimulation, and nutrient availability (27). However, functional studies investigating TSPO’s contribution to lipid metabolism have been limited. Several reports suggest that TSPO expression may respond to metabolic stress and that its pharmacological ligands modulate lipid storage phenotypes (28, 29), although the specificity and mechanism of these effects remain unclear. Given the pivotal role of mitochondria in adipocyte differentiation, lipid oxidation, and lipolysis, we considered the possibility that TSPO may directly modulate adipocyte lipid metabolism.
Unbiased discovery approaches have also implicated TSPO in adipose tissue lipid metabolism. In a genetic mapping study integrating quantitative trait loci (QTL) analysis with bioinformatic prioritization, TSPO was identified as a candidate gene influencing plasma triglyceride levels in mice (30), suggesting that natural variation at the Tspo locus may affect systemic lipid homeostasis. Independently, an exploratory screen for adipogenesis-regulated genes using differential display RT-PCR also uncovered that expression of Tspo was markedly upregulated during the differentiation of 3T3-L1 preadipocytes into mature adipocytes (31). These early findings indicated that TSPO expression dynamically responds to adipogenic stimuli. Aligned with these findings, we previously demonstrated that TSPO regulates mitochondrial fatty acid oxidation in steroidogenic cells (24), linking TSPO activity to core aspects of mitochondrial lipid metabolism. Nevertheless, direct functional evidence for TSPO in white adipose tissue remains limited.
In this study, we leveraged a multifaceted experimental strategy involving global Tspo knockout (Tspo−/−) mice, primary adipocyte cultures, and pharmacological interventions to dissect the role of TSPO in adipocyte lipid metabolism. We report that TSPO deficiency enhances lipid accumulation in adipocytes under metabolic stress, driven by suppression of canonical lipolytic pathways. Mechanistically, we identify the endogenous TSPO ligand PPIX as a potential mediator of this phenotype. Although TSPO is not essential for heme synthesis per se (32), we show that PPIX concentrations rise during adipogenesis and that excess PPIX suppresses lipolysis and adipogenic gene expression. These data suggest a previously unrecognized role for TSPO in modulating adipocyte lipid metabolism via a PPIX-dependent mechanism.
Materials and methods
Mice
The generation of Tspofl/fl and Tspo−/− mice has been previously described (7, 8). In treatment groups, 6-week-old mice were fed with either a Teklad Global standard chow diet (18% protein rodent diet; Envigo, USA) or a Teklad custom diet (45% high-fat diet, TD.06415; Envigo) for a period of 8 weeks. Feed intake and body weight were measured every 2 days. Both male and female mice were fed a HF diet from 6 to 14 weeks of age. Inguinal WAT, gonadal WAT, and liver were collected at 14 weeks of age for different measurements. Tspofl/fl and Tspo−/− mice on a standard chow diet were used for preadipocyte cultures. All animals were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and all procedures were approved by the Institutional Animal Care and Use Committee of Cornell University.
Adipocyte morphometry
Gonadal white adipose tissue (gWAT) depots were collected from male mice at 14 weeks of age following high-fat diet feeding. Tissues were fixed in 10% neutral buffered formalin for 24 h at room temperature, dehydrated through a graded ethanol series, cleared in xylene, and embedded in paraffin. Serial sections were cut at a thickness of 4 μm using a rotary microtome and mounted on glass slides. Sections were stained with Mayer’s hematoxylin solution and eosin Y alcoholic solution (both from Sigma-Aldrich, USA) following standard protocols (33). Stained sections were imaged using an inverted microscope (DM 1000 LED) equipped with an ICC50 HD digital camera (Leica, Germany). For quantification, contiguous fields were captured at 10× magnification, and adipocyte area and density were measured using ImageJ software (version 1.48v; National Institutes of Health, USA). Individual adipocytes were manually outlined, and mean adipocyte area (μm2) and cell size distribution frequencies were calculated. A minimum of 100–150 cells per sample/mouse were analyzed to ensure statistical robustness.
Preadipocyte isolation and culture
Primary preadipocytes were isolated from subcutaneous inguinal white adipose tissue (iWAT) as previously described (34). Briefly, iWAT depots were harvested from groups of male mice at 6–8 weeks of age, minced into small fragments, and digested in a solution containing collagenase from Clostridium histolyticum (Sigma-Aldrich) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma-Aldrich) in phosphate-buffered saline (PBS) at 37°C with constant shaking for 30 min. The resulting cell suspension was filtered through a 100 μm mesh to remove undigested tissue, and the stromal vascular fraction (SVF) containing preadipocytes was collected by centrifugation at 500 g for 5 min. Pelleted cells were resuspended and plated in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (P/S), and 1% non-essential amino acids (NEAA) (hereafter referred to as DMEM + FBS). Cell proliferation was monitored for expansion and replated for differentiation experiments. Fibroblast-like murine 3T3-L1 preadipocytes (American Type Culture Collection, ATCC) were cultured under identical conditions in DMEM + FBS. All cells were maintained at 37°C in a humidified incubator with 5% CO2.
Adipocyte differentiation and pharmacological treatments
Preadipocytes (primary or 3T3-L1) were cultured at 37°C in a humidified incubator with 5% CO2 in DMEM + FBS until they reached two days post-confluence (designated as day 0). To induce adipogenic differentiation, preadipocytes were treated with differentiation medium consisting of DMEM + FBS supplemented with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich), 2.5 μM dexamethasone (Sigma-Aldrich), 10 μg/mL bovine insulin (Sigma-Aldrich), and 1 μM rosiglitazone (Sigma-Aldrich) for 2 days. After two days (day 2), cells were switched to maintenance medium containing DMEM + FBS supplemented with 10 μg/mL bovine insulin alone. Maintenance medium was refreshed every day, and cells were cultured for an additional 2 days until fully differentiated, as indicated by extensive lipid droplet accumulation. For ligand treatment experiments, PK11195 (1 μM; Sigma-Aldrich) or etifoxine (1 μM; Sigma-Aldrich) was added to the culture medium beginning on day 0 and replenished with each medium change until the completion of differentiation. At timepoints, cells were collected and processed for different measurements.
Quantification of lipid accumulation
Primary preadipocytes and 3T3-L1 cells were cultured under adipogenic conditions and analyzed at day 0 (undifferentiated) and day 4 (fully differentiated) by staining for lipid accumulation as previously described (35). Cells were gently washed twice with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (Electron Microscopy Sciences) for 15 min at room temperature. Following fixation, cells were washed sequentially with double-distilled water and 60% isopropanol to prepare for staining. Lipid droplets were visualized by staining with 0.3% Oil Red O (ORO) solution (Matheson, Coleman & Bell, USA) for 30 min at room temperature. Excess stain was removed by washing with double-distilled water. For quantitative analysis, bound Oil Red O was eluted with 100% isopropanol (Mallinckrodt Chemicals, USA), and absorbance was measured at 500 nm using an Infinite F50 plate reader (Tecan, Germany). Representative images of stained cells were acquired using a Leica DMIL LED inverted microscope equipped with an MC120 HD camera.
Gene expression analysis
Total RNA was extracted from gWAT depots of male mice, primary adipocytes, and 3T3-L1 cells using TRIzol reagent (Life Technologies, USA) according to the manufacturer’s instructions. RNA concentration and purity were assessed spectrophotometrically using a NanoDrop instrument (Thermo Fisher Scientific, USA). Complementary DNA (cDNA) was synthesized from 1,000 ng of total RNA using the High-capacity cDNA reverse transcription kit (Applied Biosystems, USA), following the manufacturer’s protocol. Quantitative real-time PCR (qPCR) was performed using SYBR Green detection chemistry (Affymetrix, USA) on a StepOne Plus Real-Time PCR System (Applied Biosystems). Primer sequences were obtained from the PrimerBank database (Harvard Medical School; listed in Supplementary Table S1 (see section on Supplementary materials given at the end of the article)) and validated for specificity and amplification efficiency. The gene symbols and corresponding gene/protein names for all genes analyzed in this study are provided in Table 1. Gene expression data were normalized to TATA-binding protein (Tbp) as the reference gene. For tissue samples, normalization was performed relative to Tspofl/fl controls; for primary adipocytes, data were normalized to day 0 Tspofl/fl samples; and for 3T3-L1 cells, data were normalized to day 0 vehicle-treated control samples. Relative expression levels were calculated using the comparative Ct (2−ΔΔCt) method (36).
Table 1.
Gene nomenclature used in this study.
| Gene symbol | Gene/protein name |
|---|---|
| Tspo | Translocator protein |
| Cd36 | CD36 molecule |
| Lpl | Lipoprotein lipase |
| Glut4 | Glucose transporter type 4 |
| Srebp1c | Sterol regulatory element-binding protein 1c |
| Fasn | Fatty acid synthase |
| Acaca | Acetyl-CoA carboxylase alpha |
| Cpt1a | Carnitine palmitoyltransferase 1 A |
| Hadha | Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
| Hsl | Hormone-sensitive lipase |
| Atgl | Adipose triglyceride lipase |
| Adipoq | Adiponectin |
| Lep | Leptin |
| Il6 | Interleukin 6 |
| Pparg | Peroxisome proliferator-activated receptor gamma |
| Fabp4 | Fatty acid-binding protein 4 |
| Alas1 | 5-Aminolevulinate synthase 1 |
| Fech | Ferrochelatase |
| Tbp | TATA-box binding protein |
Western blot analysis
Western blotting was performed as previously described (33), with each experiment performed using at least two biological replicates. Briefly, samples were lysed and processed in Laemmli sample buffer containing SDS and β-mercaptoethanol (37). Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Equal amounts of protein (25 μg per sample) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). Membranes were blocked for 1 h at room temperature in 5% non-fat dry milk prepared in Tris-buffered saline containing 0.2% Tween-20 (TBS-T). Primary antibody incubations were performed overnight at 4°C using the following antibodies: rabbit anti-TSPO (EPR5384) monoclonal antibody (#ab109497, Abcam, USA), rabbit anti-HSP90 (C45G5) monoclonal antibody (#4877, Cell Signaling, USA), rabbit anti-PPARγ monoclonal antibody (Cell Signaling, #81B8), rabbit anti-FABP4 polyclonal antibody (Cell Signaling, #2120), and mouse monoclonal anti-β-actin antibody (#926-42212, Li-Cor, USA) as a loading control. After washing with TBS-T, membranes were incubated with fluorescently labeled secondary antibodies: IRDye 800CW goat anti-rabbit IgG and IRDye 680RD goat anti-mouse IgG (Li-Cor). Fluorescent signals were detected using an Odyssey infrared imaging system (Li-Cor). Selected membranes were processed for Coomassie blue staining (Thermo Scientific) and follow-up imaging to assess overall protein distribution across lanes.
Plasma NEFA quantification
Plasma non-esterified fatty acid (NEFA) concentrations were measured using the NEFA-HR (2) colorimetric assay kit (Wako Diagnostics, Japan) according to the manufacturer’s instructions. Blood was collected into EDTA-coated tubes, centrifuged at 1,500 g for 10 min at 4°C, and the plasma supernatant was stored at −80°C until analysis. Plasma samples were thawed on ice, diluted appropriately with deionized water, and loaded into a 96-well microplate along with NEFA standards. Assay reagent A, containing coenzyme A, acyl-CoA synthetase, and acyl-CoA oxidase, was added to each well and incubated at 37°C for 5 min. Following this, assay reagent B, containing peroxidase and chromogenic substrates, was added, and plates were incubated for an additional 5 min at 37°C. Absorbance was measured at 550 nm using a microplate reader (Infinite F50, Tecan). NEFA concentrations were calculated based on a standard curve generated from known NEFA concentrations. All samples and standards were assayed in duplicate.
Plasma glycerol quantification
Plasma glycerol concentrations were measured using a colorimetric enzymatic assay with the Free Glycerol Reagent (Sigma-Aldrich) according to the manufacturer’s instructions. Blood was collected into EDTA-coated tubes, centrifuged at 1,500 g for 10 min at 4°C, and the plasma supernatant was stored at −80°C until analysis. Plasma samples were thawed on ice, diluted appropriately with deionized water, and loaded into a 96-well microplate along with glycerol standards. The Free Glycerol Reagent, containing glycerol kinase, glycerol phosphate oxidase, and peroxidase enzymes, was added to each well. Following incubation at 37°C for 5 min, absorbance was measured at 540 nm using a microplate reader (Infinite F50, Tecan). Glycerol concentrations were determined by comparison to a standard curve generated from known concentrations of glycerol. All samples and standards were assayed in duplicate.
Lipidomics
Targeted lipidomics analysis of gWAT was performed using reverse-phase chromatography coupled with quadrupole time-of-flight mass spectrometry (CSH-QTOF MS), as previously described (35, 38), with minor modifications. Briefly, frozen gWAT samples were homogenized and extracted using a biphasic mixture composed of 225 μL cold methanol containing internal standards and 188 μL LC-MS grade water. Samples were vortexed and centrifuged at 14,000 g for 2 min to separate phases. The upper organic layer (350 μL), enriched in lipids, was collected and dried using a vacuum centrifuge (Labconco, USA). Dried lipid extracts were reconstituted in 110 μL of 90:10 methanol:toluene containing 50 ng/mL CUDA (Cayman Chemical, USA) and analyzed using an Agilent 1,290 Infinity LC system. Samples were analyzed in both positive and negative electrospray ionization (ESI) modes to broaden lipid coverage. For ESI (+) mode, mobile phases were modified with 10 mM ammonium formate and 0.1% formic acid, which enhanced detection of CE, DG, and PC classes. For ESI (−) mode, 10 mM ammonium acetate was used. Lipid separation was performed using an Acquity UPLC CSH C18 column (100 × 2.1 mm, 1.7 μm) with a matching VanGuard pre-column (5 × 2.1 mm, 1.7 μm) maintained at 65°C and a flow rate of 0.6 mL/min. The mobile phase consisted of 60:40 acetonitrile:water (A) and 90:10 isopropanol:acetonitrile (B), with a gradient elution profile optimized for broad lipid class resolution. Lipids were detected using an Agilent 6550 iFunnel QTOF mass spectrometer with jet stream ESI source. Acquisition was performed over an m/z range of 50–1,700 at a rate of 2 spectra/s. QC included method blanks and pooled plasma standards. Data were processed using MS-DIAL software. Lipids were annotated using an in-house retention time and accurate mass library based on LipidBlast. The neutral lipids were further subcategorized into TG, DG, and total cholesterol. The percentage expression (peak height) of these subcategories was calculated relative to the total neutral lipid expression. All analyses and heatmap representations were performed using R (https://www.r-project.org/).
PPIX measurement
Concentrations of PPIX in WAT and cultured primary adipocytes were quantified using a modified fluorometric assay as previously described (32). For tissue analysis, freshly harvested WAT was homogenized in 1% Triton X-100 in Tris-buffered saline (TBS) and centrifuged at 5,000 g for 10 min at 4°C. PPIX fluorescence was measured in the supernatant using a fluorescence spectrophotometer (Infinite 200, Tecan) with excitation at 400 nm and emission at 660 nm. For cultured cells, primary preadipocytes were harvested at the indicated time points (days 0, 2, and 4), collected by trypsinization, neutralized in serum-containing DMEM, and lysed in a 1:1 mixture of methanol and 1 N perchloric acid (MeOH-PCA) on ice for 10 min. Lysates were centrifuged at 10,000 g for 10 min at 4°C, and PPIX fluorescence was measured in black 96-well plates under identical spectrophotometric settings. In all cases, PPIX concentrations were determined using a standard curve prepared with PPIX (Sigma-Aldrich) and normalized to tissue weight or total protein content in each sample as measured by BCA.
Statistics
All quantitative experiments were performed using at least three independent biological replicates. Data are presented as mean ± standard error of the mean (SEM). Statistical analyses were conducted using GraphPad Prism v9 (GraphPad Software, USA). For pairwise comparisons, Student’s t-tests were used. For multiple group comparisons, one-way ANOVA followed by Tukey’s post hoc test was applied. A P-value of <0.05 was considered statistically significant. Statistical outcomes are provided in the figure legends. No data points were excluded from the analyses.
Results
TSPO deficiency increases white adipose tissue mass
To determine the impact of TSPO deficiency under conditions of metabolic stress, we compared body weight trajectories, adipose tissue mass, and feed intake in Tspofl/fl and Tspo−/− mice subjected to high-fat (HF) diet feeding. At baseline (6 weeks of age), there were no significant differences in total body weight between genotypes in either males or females (Fig. 1A). Over the 8-week HF diet period, male Tspofl/fl and Tspo−/− mice maintained similar body weight trajectories, whereas female Tspo−/− mice exhibited a modest but significant increase in body weight relative to Tspofl/fl female mice beginning at week 7 (Fig. 1B). Analysis of adipose depot mass showed a common genotype-associated phenotype: gonadal (gWAT) and inguinal (iWAT) white adipose tissue depot weights were significantly increased in both male and female Tspo−/− mice compared with controls following HF diet feeding, while liver weights remained unchanged (Fig. 1C). Daily feed intake during the HF diet period was comparable between genotypes (Fig. 1D), indicating that the enhanced adipose tissue expansion observed in Tspo−/− mice was not attributable to differences in caloric intake.
Figure 1.

TSPO deficiency increases white adipose depot mass following high-fat diet feeding. (A) Body weights of Tspofl/fl and Tspo−/− male and female mice at baseline showed no significant differences between genotypes (8 weeks old; n = 10 per group). (B) Body weight gain trajectories over the 8-week high-fat (HF) diet period revealed no significant genotype effect in males, but showed significant increases after 7 weeks of HF diet in female Tspo−/− mice (*P < 0.05; n = 10 per group for males and females). (C) Representative Western blots confirming global lack of TSPO protein expression in the adrenal, gonadal WAT (gWAT), and inguinal WAT (iWAT) in Tspo−/− mice compared with Tspofl/fl controls. Protein loading stains (pc) or HSP90 expression are shown for each tissue. (D) Quantification of white adipose tissue (WAT) depots indicated a significant increase in gWAT and iWAT weights in Tspo−/− mice compared with Tspofl/fl controls in both sexes following HF diet feeding (n = 10 per group). Liver weights remained unchanged. (E) Daily feed intake (g/day) was not significantly different between Tspofl/fl and Tspo−/− mice during the 8-week HF diet period, indicating that the enhanced WAT expansion was independent of differences in caloric intake. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05).
TSPO deficiency promotes adipocyte hypertrophy
We next assessed whether TSPO deficiency alters adipocyte morphology in gWAT from male mice under baseline and HF diet conditions. Histological analysis of gWAT sections from chow-fed mice revealed no overt differences in adipocyte size between Tspofl/fl and Tspo−/− genotypes (Fig. 2A). Quantification of adipocyte area and cell size distribution confirmed that TSPO deficiency did not significantly impact adipocyte size under standard chow conditions (Fig. 2B). In contrast, after 8 weeks of HF diet feeding, gWAT sections from Tspo−/− mice showed visibly enlarged adipocytes compared with Tspofl/fl controls (Fig. 2C). Morphometric analysis demonstrated a significant increase in mean adipocyte area in Tspo−/− mice, accompanied by a rightward shift in the overall distribution of adipocyte sizes (Fig. 2D). These findings indicate that loss of TSPO promotes adipocyte hypertrophy in response to high-fat diet-induced metabolic stress.
Figure 2.

TSPO deficiency promotes adipocyte hypertrophy in gonadal white adipose tissue following high-fat diet feeding. (A) Representative hematoxylin and eosin-stained sections of gonadal white adipose tissue (gWAT) from Tspofl/fl and Tspo−/− mice under standard chow conditions. (B) Under standard chow, quantification of adipocyte area revealed no significant differences between genotypes, as shown by mean adipocyte area (right) and cell size distribution frequency (left; n = 1,344 cells per group). (C) Representative hematoxylin and eosin-stained sections of gWAT from Tspofl/fl and Tspo−/− mice following high-fat diet feeding show adipocyte hypertrophy. (D) Following 8 weeks of HF diet, Tspo−/− adipocytes were significantly larger than Tspofl/fl adipocytes, with increased mean cell area (left) and a rightward shift in cell size distribution (right; n = 360 cells per group). Statistical significance for mean adipocyte area comparisons and distribution comparisons is indicated (*P < 0.05).
Loss of TSPO alters lipid metabolism gene expression in gWAT
To investigate the metabolic processes underlying the enhanced lipid accumulation observed in Tspo−/− mice, we analyzed the expression of genes involved in nutrient uptake, fatty acid (FA) synthesis, FA oxidation, lipolysis, and adipokine secretion in gWAT from mice fed either the standard chow diet or the HF diet. For genes involved in nutrient uptake, Tspo−/− gWAT under a chow diet did not exhibit significant changes in the expression of Cd36, Lpl, or Glut4 compared with controls (Fig. 3A). However, after HF diet feeding, Lpl expression was significantly downregulated in Tspo−/− gWAT, while Cd36 and Glut4 expression remained unchanged (Fig. 3A). Among FA synthesis-related genes, chow-fed Tspo−/− mice showed significant downregulation of Srebp1c and Acaca, with no difference in Fasn expression compared with Tspofl/fl cohorts (Fig. 3B), indicating an altered lipogenic program. Following HF diet feeding, Acaca expression remained significantly lower in Tspo−/− gWAT, but Srebp1c and Fasn levels were comparable to controls (Fig. 3B). In the mitochondrial β-oxidation pathway (fatty acid oxidation, FAO), no significant differences were observed in the expression of Cpt1a or Hadha in chow-fed Tspo−/− mice (Fig. 3C). By contrast, after HF diet feeding, Tspo−/− gWAT exhibited significant downregulation of both Cpt1a and Hadha (Fig. 3C), indicating diminished FAO in Tspo−/− gWAT. For genes regulating lipolysis, expression of Hsl and Atgl was not significantly altered by TSPO deficiency under chow diet conditions (Fig. 3D). After HF diet feeding, however, Tspo−/− gWAT showed a significant decrease in Hsl expression and a downward trend in Atgl expression (Fig. 3D), indicating reduced lipolysis in Tspo−/− WAT. Finally, among adipokine genes, chow-fed Tspo−/− mice exhibited reduced Adipoq expression and elevated Lep expression, with no difference in Il6 levels (Fig. 3E). Under HF diet conditions, expression of Adipoq and Il6 was not significantly different between genotypes; however, expression of Lep was significantly lower in Tspo−/− mice (Fig. 3E). These findings demonstrate that while TSPO deficiency causes selective, inconsistent alterations in lipid metabolism gene expression under chow diet, it leads to more pronounced and coordinated changes following HF diet feeding.
Figure 3.

TSPO deficiency alters lipid metabolism gene expression in gonadal white adipose tissue following high-fat diet feeding. (A) Relative mRNA expression of lipid uptake and glucose transport genes (Cd36, Lpl, Glut4) in gonadal white adipose tissue (gWAT). Expression of Lpl was significantly downregulated in Tspo−/− mice after 8 weeks of HF diet feeding, whereas Cd36 and Glut4 levels were not significantly altered based on genotype. (B) Relative mRNA expression of lipogenesis-related genes (Srebp1c, Fasn, Acaca). Expression of Acaca was significantly downregulated in Tspo−/− mice after 8 weeks of HF diet feeding, whereas Srebp1c and Fasn were not significantly altered based on genotype. (C) Relative mRNA expression of fatty acid oxidation genes (Cpt1a, Hadha) in gWAT. Expression of Cpt1a and Hadha was significantly downregulated in Tspo−/− mice after 8 weeks of HF diet feeding. (D) Relative mRNA expression of the lipolytic enzymes (Hsl and Atgl) in gWAT. Expression of Hsl was significantly downregulated in Tspo−/− mice after 8 weeks of HF diet feeding, whereas Atgl showed a decreasing trend that was not statistically significant. (E) Relative mRNA expression of adipokine genes (Lep, Adipoq, and Il6) revealed significant downregulation of Lep in Tspo−/− mice after 8 weeks of HF diet feeding, whereas Adipoq and Il6 were not significantly altered based on genotype. (F) Circulating non-esterified fatty acid (NEFA) concentrations measured in serum showed significant downregulation in Tspo−/− mice on both standard chow and HF diets. (G) Circulating serum glycerol concentrations also showed significant downregulation in Tspo−/− mice after 8 weeks of HF diet feeding. (H) Representative Western blots for TSPO and HSP90 protein expression in gWAT under standard chow and HF diet conditions did not show any notable differences between chow and HF diet feeding in Tspofl/fl mice. Data are presented as mean ± SEM. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05).
TSPO deficiency reduces circulating NEFA and glycerol
To confirm a functional impact on lipolysis, we measured circulating levels of non-esterified fatty acids (NEFA) and glycerol, key products of triglyceride breakdown. Consistent with reduced lipolytic gene expression, Tspo−/− mice exhibited significantly lower plasma NEFA concentrations compared with Tspofl/fl controls under both chow and HF diet conditions (Fig. 3F). Plasma glycerol concentrations were also significantly reduced in Tspo−/− mice following HF diet feeding, although no significant difference was observed under chow diet (Fig. 3G). Finally, to determine whether the HF diet influenced TSPO expression itself, we assessed TSPO protein levels in gWAT by Western blot analysis and found no appreciable differences between chow-fed and HF diet-fed Tspofl/fl mice (Fig. 3H). These data indicate that TSPO deficiency lowers circulating lipolytic products.
Lipidomic profiling reveals no major impact of TSPO deficiency on gWAT lipid composition
To assess whether TSPO deficiency alters lipid composition, we performed targeted lipidomic analysis of gWAT. A total of 71 annotated lipid species were detected across four major classes: free fatty acids (FAs), diacylglycerols (DGs), triacylglycerols (TGs), and cholesterol. Heatmap visualization revealed diet-dependent clustering, with HF diet samples exhibiting some distinctions among the different lipids relative to chow-fed controls, regardless of TSPO genotype (Fig. 4). Among FAs, species such as FA (18:3) were consistently lower in the HF diet in both genotypes. Among DGs, species such as DG (34:1) and DG (36:2) were consistently elevated in the HF diet in both genotypes. Among TGs, species such as TG (56:7) and TG (58:10) were consistently lower in both Tspofl/fl and Tspo−/− mice under the HF diet. Regardless, no consistent genotype-specific differences were observed within either dietary group with minor variability across individual samples but no evidence of systematic shifts due to TSPO deletion. These data demonstrate that TSPO deficiency does not appreciably affect the abundance or distribution of major lipid species in gWAT, and that lipid composition changes with high-fat diet are preserved in the absence of TSPO.
Figure 4.

TSPO deficiency does not alter lipid composition in gonadal white adipose tissue at baseline or after high-fat diet. Relative abundance of detected lipid species was quantified and visualized as a heatmap. Each row represents a lipid species categorized by lipid class: cholesterol, free fatty acids (FA), diacylglycerols (DG), and triacylglycerols (TG). Columns represent individual biological replicates from four groups: Tspofl/fl mice and Tspo−/− mice on standard chow; Tspofl/fl and Tspo−/− mice on 8 weeks of high-fat diet as indicated. Lipid signal intensity is color-coded on a dual scale (low range – from 500-5E5 peak height; high range from 5E5 to 1E7). Standard chow and high-fat diet conditions exhibit some minor distinctions in lipid abundance patterns, but there were no notable compositional differences between gWAT from Tspofl/fl mice and Tspo−/− mice.
TSPO deficiency enhances lipid accumulation in primary iWAT-derived preadipocytes
To determine whether cell-intrinsic consequences of TSPO deficiency affect adipocyte differentiation and lipid metabolism in vitro, we compared lipid accumulation, protein expression, and metabolic gene profiles in primary preadipocytes isolated from Tspofl/fl and Tspo−/− iWAT. Oil Red O staining at day 4 of differentiation revealed greater lipid accumulation in Tspo−/− adipocytes compared with Tspofl/fl controls (Fig. 5A), a finding confirmed by quantification of Oil Red O absorbance (Fig. 5B). Quantitative PCR analysis in Tspofl/fl adipocytes showed progressive induction of Tspo mRNA expression over the course of differentiation (Fig. 5C). Representative Western blots demonstrated an expected increase in PPARγ protein levels during differentiation, confirming successful adipogenic induction; TSPO protein also showed an apparent increase over the course of differentiation in Tspofl/fl cells, and HSP90 levels remained relatively stable across time points (Fig. 5C). Representative Western blots of day 4 adipocytes from two independent cohorts showed apparent reduction in PPARγ and FABP4 protein levels in Tspo−/− adipocytes relative to Tspofl/fl controls (Fig. 5E). We also assessed the expression of key genes involved in nutrient uptake, fatty acid metabolism, and adipogenesis at days 0 and 4 of differentiation. At day 0, undifferentiated Tspo−/− preadipocytes exhibited significant upregulation of Hsl (Fig. 5F). At day 4, differentiated Tspo−/− adipocytes exhibited significant downregulation of Fabp4, Acaca, and both major lipolytic enzymes Hsl and Atgl compared with Tspofl/fl controls (Fig. 5F). Expression of other nutrient transport and adipogenic markers remained largely unchanged between genotypes (Fig. 5F). Together, the increased lipid accumulation and reduced expression of key components of the lipolytic pathway indicate altered lipid handling in Tspo−/− adipocytes during differentiation.
Figure 5.

TSPO deficiency enhances lipid accumulation in differentiation of primary preadipocytes from inguinal white adipose tissue. (A) Representative Oil Red O staining of iWAT-derived primary adipocytes from Tspofl/fl and Tspo−/− mice at day 4 of differentiation under adipogenic conditions indicated higher abundance of lipid accumulation in Tspo−/− adipocytes. (B) Graph showing quantification of lipid accumulation by Oil Red O absorbance at day 0 and day 4 of differentiation. Tspo−/− adipocytes showed significantly higher levels of lipid accumulation compared with Tspofl/fl controls. (*P < 0.05) (C) Quantitative PCR analysis of Tspo mRNA expression during differentiation (days 0, 2, and 4) in Tspofl/fl adipocytes demonstrates robust induction of Tspo transcript levels over the course of adipogenesis. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05). (D) Representative Western blots showing TSPO, PPARγ, and HSP90 protein levels at days 0, 2, and 4 of differentiation in Tspofl/fl adipocytes. The blots illustrate the expected differentiation-associated expression levels; actin is shown as a loading control. (E) Representative Western blots showing PPARγ and FABP4 protein expression in day 4 adipocytes from two independent replicate samples of Tspofl/fl and Tspo−/− mice. Qualitative differences in band intensity suggest lower PPARγ and FABP4 protein expression in Tspo−/− cells; actin serves as a loading control. (F) Relative mRNA expression of adipogenesis-associated genes (Pparg, Fabp4, Cd36, Lpl, Glut4, Srebp1c, Fasn, Acaca, Hsl, and Atgl) in Tspofl/fl and Tspo−/− adipocytes at days 0 and 4. Expression was normalized to the mean Tspofl/fl day 0 (1-fold), with biological variance retained, and the same reference was used across genotypes and differentiation states. At day 4, Tspo−/− adipocytes exhibited significant downregulation of Fabp4, Acaca, Hsl, and Atgl, consistent with impaired adipogenic and lipolytic gene programs (mean ± SEM; *P < 0.05). Day 4 graph is separated solely for visual clarity.
Pharmacological modulation of TSPO impacts adipocyte differentiation
To assess whether pharmacological modulation of TSPO affects adipocyte differentiation, we treated primary adipocytes derived from Tspofl/fl and Tspo−/− iWAT with the TSPO-binding drugs PK11195 or etifoxine. As shown by Oil Red O staining at day 4, Tspo−/− adipocytes accumulated significantly more lipid than Tspofl/fl controls under basal conditions, consistent with previous observations (Fig. 6A). Notably, treatment of Tspofl/fl adipocytes with either PK11195 or etifoxine increased lipid accumulation to levels comparable to untreated Tspo−/− cells (Fig. 6A and B), suggesting that TSPO-binding drugs phenocopy the knockout state. Supporting this interpretation, PK11195 and etifoxine treatment had no enhancing effect on the already higher level of lipid accumulation observed in Tspo−/− adipocytes (Fig. 6B).
Figure 6.

Pharmacological modulation of TSPO impairs adipocyte differentiation. (A) Representative Oil Red O staining of iWAT-derived primary adipocytes from Tspofl/fl and Tspo−/− mice treated during differentiation with vehicle control, PK11195 (1 μM), or etifoxine (1 μM). Higher levels of lipid accumulation could be observed in Tspofl/fl adipocytes with PK11195 and etifoxine treatments. (B) Quantification of lipid accumulation by Oil Red O absorbance (520 nm) in primary adipocytes showed increased lipid accumulation following PK11195 and etifoxine treatments in Tspofl/fl adipocytes to levels that were comparable to Tspo−/− adipocytes. PK11195 and etifoxine had no effect on the already significantly higher levels of lipid accumulation seen in Tspo−/− adipocytes. (C) Representative Oil Red O staining of 3T3-L1 preadipocytes differentiated in the presence of vehicle control, PK11195, or Etifoxine. Higher levels of lipid accumulation could be observed in 3T3-L1 adipocytes with PK11195 and etifoxine treatments. (D) Quantification of lipid accumulation by Oil Red O absorbance in 3T3-L1 adipocytes showed increased lipid accumulation following PK11195 and etifoxine treatments. Data are presented as mean ± SEM. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05).
Having established the genotype-dependent phenotype and pharmacology in primary adipocytes, we used 3T3-L1 cells as an independent, standardized adipogenic system for testing TSPO pharmacological manipulation. 3T3-L1 cells were treated with PK11195 or etifoxine under standard differentiation conditions. Both compounds significantly increased lipid accumulation (Fig. 6C and D), consistent with findings in Tspofl/fl primary cells. Taken together, these findings demonstrate that pharmacological binding of TSPO enhances adipogenesis in a manner that mimics genetic deletion of the protein.
TSPO regulates porphyrin homeostasis
To investigate whether TSPO influences porphyrin and heme biosynthesis during adipogenesis, we first quantified protoporphyrin IX (PPIX) concentrations and the expression of key porphyrin and heme biosynthetic enzymes in gWAT. At baseline, PPIX levels in gWAT were comparable between Tspofl/fl and Tspo−/− mice (Fig. 7A). Gene expression analyses under baseline and HF diet conditions showed that Tspo−/− mice exhibited significantly reduced expression of Alas1 (δ-aminolevulinic acid synthase) and Fech (ferrochelatase), the first and last enzymes in the heme biosynthesis pathway, respectively, relative to Tspofl/fl controls (Fig. 7B).
Figure 7.

TSPO deficiency alters porphyrin and heme biosynthesis gene expression in white adipose tissue and during adipocyte differentiation. (A) Baseline protoporphyrin IX (PPIX) concentrations measured in gWAT were not different between Tspofl/fl and Tspo−/− mice under standard chow conditions. (B) Relative mRNA expression of δ-aminolevulinic acid synthase (Alas1) and ferrochelatase (Fech) in gWAT under HF diet conditions showed significant downregulation in Tspo−/− mice compared with Tspofl/fl controls. (C and D) During in vitro differentiation of adipocytes from iWAT, Tspo−/− primary adipocytes showed significantly elevated expression of Alas1 and Fech at days 2 and 4 compared with Tspofl/fl cells, suggesting dysregulation of porphyrin and heme biosynthetic genes in the absence of TSPO. (E) Adipogenic gene expression in Tspofl/fl primary adipocytes treated with δ-aminolevulinic acid (ALA), protoporphyrin IX (PPIX), or hemin during differentiation at day 4. Treatment with ALA and PPIX significantly reduced mRNA levels of the adipogenic markers Pparg and Fabp4, whereas hemin had no significant effect. Data are presented as mean ± SEM. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05).
During in vitro adipocyte differentiation of primary adipocytes from Tspofl/fl and Tspo−/− iWAT, expression of both Alas1 and Fech was markedly upregulated in Tspo−/− primary adipocytes compared with Tspofl/fl cells, with significant differences observed at both days 2 and 4 of differentiation (Fig. 7C and D). These data suggest that TSPO deficiency leads to alterations in the regulation of porphyrin and possibly heme biosynthesis.
To assess whether modulation of porphyrin pathway intermediates directly impacts adipogenic gene expression, we treated Tspofl/fl primary iWAT-derived preadipocytes with δ-aminolevulinic acid (ALA), PPIX, or hemin during differentiation. Both ALA and PPIX at day 4 significantly suppressed expression of the adipogenic markers Pparg and Fabp4, whereas hemin had no effect on their expression (Fig. 7E). These findings indicate that the accumulation of upstream porphyrin intermediates negatively regulates adipocyte differentiation, and that TSPO may influence adipogenesis in part by modulating porphyrin levels.
PPIX accumulation inhibits adipocyte differentiation and lipolytic responses
To investigate whether porphyrin biosynthetic intermediates modulate adipocyte function, we first measured intracellular PPIX levels during 3T3-L1 adipocyte differentiation. PPIX levels increased progressively from day 0 to day 4, indicating enhanced flux through the porphyrin synthesis pathway during adipogenesis (Fig. 8A). Consistent with this, Alas1 mRNA, encoding the rate-limiting enzyme in porphyrin biosynthesis, was significantly upregulated during differentiation. By contrast, Fech, which catalyzes the terminal step converting PPIX to heme, showed a declining expression pattern (Fig. 8B), suggesting a potential accumulation of porphyrin intermediates.
Figure 8.

Porphyrin intermediates inhibit adipocyte differentiation and lipolytic responses. (A) Cellular protoporphyrin IX (PPIX) levels increase progressively during 3T3-L1 differentiation, linking porphyrin biosynthesis to adipogenic progression. (B) Alas1 and Fech mRNA expression during differentiation revealed a significant upregulation of Alas1 by day 4 and downregulation of Fech by day 2, indicating activation of porphyrin synthesis with reduced terminal heme synthesis. (C and D) Representative Oil Red O staining and quantification of lipid accumulation in 3T3-L1 cells treated with ALA (1 mM), PPIX (1 μM), or hemin (10 μM) at day 4 of differentiation. ALA and PPIX significantly reduced lipid accumulation, whereas hemin promoted it, suggesting that upstream porphyrins, but not heme, suppress adipogenesis. (E) Glycerol release at 4- and 8-hours post-treatment with ALA (1 mM), ALA + Bt2cAMP (0.5 mM), or Bt2cAMP alone showed that ALA significantly suppressed cAMP-stimulated lipolysis. Bars represent mean ± SEM. Statistical groupings are indicated by letters; groups with no letters in common differ significantly (P < 0.05).
To test the functional significance of porphyrin intermediates, 3T3-L1 cells were treated with δ-aminolevulinic acid (ALA), PPIX, or hemin from day 0 to day 4 of differentiation. Oil Red O staining revealed that both ALA and PPIX treatments significantly reduced lipid accumulation compared with control, whereas hemin treatment had the opposite response significantly increasing lipid accumulation in differentiated 3T3-L1 cells (Fig. 8C). These results indicated that PPIX, but not heme, impairs adipocyte differentiation.
We next assessed the impact of porphyrin intermediates on lipolytic responses in mature adipocytes. Glycerol release assays demonstrated that ALA treatment suppressed both basal and cAMP-stimulated lipolysis at 4- and 8-h post-treatment (Fig. 8D), indicating that porphyrin accumulation also negatively regulates lipolytic pathways. These findings suggest that dysregulation or accumulation of porphyrin intermediates and PPIX selectively impairs both adipogenic and lipolytic programs in adipocytes, independent of terminal heme synthesis.
Discussion
The long-held assumption that the translocator protein (TSPO) facilitates mitochondrial cholesterol import for steroidogenesis has been unequivocally overturned by genetic studies showing normal hormone biosynthesis in TSPO knockout models (7, 8, 39). This conceptual shift is now reinforced by resolution of the STAR/STARD1 mechanism, which identifies STAR as the intermembrane space cholesterol shuttle responsible for acute mitochondrial cholesterol transfer independent of TSPO (9). However, an explanation for high TSPO expression in both steroidogenic and non-steroidogenic cells that are metabolically active in lipid turnover remains unclear. Our previous work demonstrated that TSPO deletion in Leydig cells leads to a metabolic reprogramming favoring mitochondrial fatty acid oxidation (FAO), despite unaltered steroidogenic output (24). In parallel, we reported that TSPO expression in hamster adrenals is tightly linked to triglyceride handling rather than hormone biosynthesis, implicating a broader role for TSPO in lipid metabolic regulation (26). The current study expands this framework to adipocyte metabolism using complementary in vivo, primary cell, and pharmacological approaches that interrogate TSPO function at different biological levels, revealing a distinctive porphyrin-sensitive metabolic phenotype associated with TSPO loss.
We found no apparent metabolic perturbations at baseline in Tspo−/− mice, consistent with previous reports showing normal body weight, food intake, and adiposity under standard chow-fed conditions (40). However, exposure to the HF diet unmasked a robust adipose phenotype characterized by increased gWAT and iWAT mass and adipocyte hypertrophy, despite unchanged feed intake in Tspo−/− mice; an additional increase in total body weight emerged only in female Tspo−/− mice during the latter portion of HF diet feeding. The basis of this female-specific body weight difference may reflect an interaction between TSPO deficiency and secondary sex-dependent physiological factors, including hormonal and reproductive regulation, rather than a difference in the primary function of TSPO in cells. Analyses of molecular mechanisms were performed in males and, therefore, should not be extrapolated to the metabolic consequences at the latter stages in female mice. Determining how sex-dependent physiology modifies the broader metabolic consequences of TSPO deficiency in vivo will require purpose-designed genotype-by-sex experiments in the future.
The increase in gWAT depots in Tspo−/− mice was not attributable to enhanced nutrient uptake or lipogenesis, as expression of Cd36, Glut4, Fasn, and Srebp1c remained unchanged or was suppressed. Instead, the phenotype reflected impaired lipid clearance: expression of the canonical lipolytic enzymes Hsl and Atgl was significantly reduced, accompanied by a decrease in Lpl and circulating glycerol and non-esterified fatty acids. Notably, NEFA levels were already significantly lower in chow-fed Tspo−/− mice, suggesting a suppression of basal lipolysis that becomes exacerbated under conditions of metabolic stress. These data point to a cell-autonomous deficit in triglyceride mobilization. This impairment also extended to the transcriptional suppression of mitochondrial FAO genes (Cpt1a, Hadha), suggesting altered coordination between triglyceride mobilization and downstream FAO. Importantly, lipidomic profiling of gWAT revealed that neither baseline lipid composition nor HF diet-induced lipid species enrichment was significantly altered by TSPO deficiency. High-fat feeding robustly increased long-chain and unsaturated triacylglycerols across genotypes, indicating that the observed adipocyte lipid accumulation in Tspo−/− mice might not be due to aberrant lipid uptake or storage but is rather consistent with reduced lipid mobilization. This decoupling is especially evident under conditions of metabolic overload, where intact TSPO appears necessary to maintain lipid flux and prevent excessive lipid accumulation in adipocytes.
A striking mechanistic insight from this study is the identification of PPIX, a long-known endogenous TSPO ligand (41) and an intermediate in the heme biosynthesis pathway, as a negative regulator of adipocyte lipid metabolism. During adipogenesis, intracellular PPIX levels rise, and we found that providing PPIX or its precursor ALA in excess selectively suppressed adipogenic and lipolytic gene expression, while hemin, representing the terminal product of the pathway, had no such effect. These results implicate porphyrin intermediates, rather than heme, as bioactive modulators of adipocyte function. Notably, Tspo transcript and protein levels increased during adipocyte differentiation, consistent with prior reports demonstrating TSPO upregulation in response to adipogenic cues (31), suggesting that enhanced TSPO expression may serve a functional role in buffering or regulating porphyrin accumulation during this transition. However, the mechanism by which PPIX suppresses adipogenic and lipolytic gene programs remains unresolved.
The loss of TSPO altered the expression dynamics of porphyrin biosynthetic enzymes: Alas1, the first and rate-limiting enzyme of the porphyrin biosynthetic pathway (42), and Fech, which catalyzes the conversion of PPIX to heme (43), were diminished in vivo under the HF diet, whereas both Alas1 and Fech were transcriptionally upregulated during in vitro differentiation. This suggests that TSPO acts to constrain the accumulation or signaling activity of porphyrin intermediates, possibly through binding, sequestration, or facilitating their mitochondrial processing (44, 45, 46). In its absence, dysregulated porphyrin metabolism may impair mitochondrial function and directly suppress the transcriptional programs required for lipid mobilization. This TSPO–PPIX axis provides a previously unrecognized mechanism by which mitochondrial tetrapyrrole metabolism intersects with adipocyte bioenergetics and lipid turnover.
Our use of the TSPO-binding drugs PK11195 and etifoxine provided a critical pharmacological lens through which to validate the metabolic functions of TSPO identified in the genetic model. Both ligands recapitulated the key phenotype of TSPO deficiency, namely enhanced lipid accumulation in iWAT-derived Tspofl/fl primary adipocytes. Importantly, there was no effect on Tspo−/− primary adipocytes, confirming that these actions are mediated specifically through TSPO rather than off-target effects. Nonetheless, it is important to recognize that both PK11195 (39) and etifoxine (47) are known to exhibit additional pharmacological activities. Both PK11195, an isoquinoline carboxamide, widely considered the prototypical non-benzodiazepine TSPO-binding drug (48), and etifoxine, a clinically used anxiolytic that binds TSPO with a distinct pharmacology (49, 50), similarly disrupted adipocyte lipid metabolism in our study, supporting a conserved mechanism of TSPO-dependent regulation (51). Given the complexity of TSPO–drug interactions, which may be modulated by the lipid environment, and ligand-specific conformational shifts (52), our findings argue for a cautious interpretation of TSPO-targeted interventions in both experimental and clinical settings. The ability of these ligands to mimic genetic deletion effects also opens the possibility that specific ligand classes may differentially bias the TSPO–PPIX axis toward lipid-retentive or lipid-mobilizing states, offering a potential framework for the development of next-generation TSPO modulators with tailored metabolic effects.
The emerging paradigm from this and related studies is that TSPO modulates mitochondrial lipid metabolism through porphyrins as regulatory intermediates that are evolutionarily conserved. Cross-species investigations support this broader view: in plants, TSPO modulates tetrapyrrole regulation under stress conditions (45), and in cyanobacteria, TSPO binds diverse porphyrins and may act as a control for tetrapyrrole metabolism (46). In mammalian systems, TSPO loss has been linked to altered mitochondrial respiration and shifts in substrate utilization in microglia (53), macrophages (54), and retinal pigment epithelial cells (55), many of which demonstrate compensatory reliance on glycolysis or disrupted FAO. Our findings in adipocytes extend these observations by showing that TSPO deficiency impairs lipolysis and FAO in association with PPIX-based metabolic coordination. Importantly, our prior work in TSPO-enriched steroidogenic cells showed altered mitochondrial FAO without ultrastructural defects or broad disruption of core mitochondrial respiration (8, 24), suggesting that TSPO-dependent metabolic effects do not necessarily reflect a generalized mitochondrial dysfunction. Recent studies further indicate that TSPO’s interaction with PPIX involves structural features of its binding pocket (56) and may be associated with catalytic activity (57), providing a plausible molecular basis for porphyrin-dependent regulation of mitochondrial processes. Although recent studies have taken steps to define TSPO as a PPIX oxygenase (58), the activity is observed only under photoactivated conditions, with no evidence of an enzymatic function in the absence of light or native mitochondrial conditions relevant for mammalian in vivo systems. These insights, combined with functional studies showing that TSPO can ameliorate PPIX pathogenesis (59, 60), support the model that TSPO serves as a critical interface between lipid mobilization, oxidative metabolism, and regulation of tetrapyrrole levels.
This study was not intended as a comprehensive characterization of adipose physiology in the global Tspo−/− mouse, but rather to investigate the molecular function of TSPO using adipocyte lipid metabolism as a tractable phenotype. Taken together, our findings indicate that TSPO is a homeostatic modulator of PPIX regulation of lipid metabolism in adipocytes. Building on our prior work on TSPO in Leydig cells and adrenal tissues, our finding showing that PPIX, an endogenous TSPO ligand, suppresses both adipogenic and lipolytic programs reveals a novel mechanism through which mitochondrial tetrapyrrole flux can influence lipid turnover. The capacity of TSPO to modulate this axis and the ability of its pharmacological ligands to phenocopy its deficiency redefine the functional landscape of this enigmatic protein. These insights carry substantial implications for interpreting TSPO biology across disciplines, from neuroinflammation to metabolic disease, and raise the prospect that tissue-specific TSPO activity may govern discrete metabolic control through differential porphyrin flux. By reframing TSPO as a lipid-metabolic integrator, this work opens new directions for defining how porphyrin handling links TSPO activity to adipocyte lipid turnover, signaling, transcriptional regulation, and metabolic adaptation.
Supplementary materials
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
Funding for this study was from the National Institutes of Health (Grant Number DK110059) to VS.
Data availability
All data supporting the findings of this study are available within the article and its Supplementary materials.
Acknowledgments
We are thankful for fellowship support from the Vietnam Education Foundation to Lan N. Tu and for partial research support from the Dextra Undergraduate Research Fund at Cornell University to Carmen Smith. We also thank Meghan Showalter and Oliver Fiehn at UC Davis for lipidomic services. The authors gratefully acknowledge the contributions of all current and former members of the Selvaraj Laboratory of Integrative Physiology, whose efforts and insights have shaped the direction of this work. We further thank Dr Yves Boisclair and his laboratory at Cornell for valuable discussions that helped refine the conceptual framework of this study and enabled some of the discoveries presented here.
References
- 1.Braestrup C & Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci U S A 1977. 74 3805–3809. ( 10.1073/pnas.74.9.3805) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Anholt RRH, Pedersen PL, De Souza EB, et al. The Peripheral-type benzodiazepine receptor, localization to the mitochondrial outer membrane. J Biol Chem 1986. 261 576–583. ( 10.1016/s0021-9258(17)36131-8) [DOI] [PubMed] [Google Scholar]
- 3.Mukhin AG, Papadopoulos V, Costa E, et al. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc Natl Acad Sci U S A 1989. 86 9813–9816. ( 10.1073/pnas.86.24.9813) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Papadopoulos V, Mukhin AG, Costa E, et al. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J Biol Chem 1990. 265 3772–3779. ( 10.1016/s0021-9258(19)39661-9) [DOI] [PubMed] [Google Scholar]
- 5.Li H, Yao Z, Degenhardt B, et al. Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci U S A 2001. 98 1267–1272. ( 10.1073/pnas.031461598) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Banati RB, Middleton RJ, Chan R, et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun 2014. 5 5452. ( 10.1038/ncomms6452) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Morohaku K, Pelton SH, Daugherty DJ, et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 2014. 155 89–97. ( 10.1210/en.2013-1556) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tu LN, Morohaku K, Manna PR, et al. Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. J Biol Chem 2014. 289 27444–27454. ( 10.1074/jbc.M114.578286) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Koganti PP, Zhao AH, Kern MC, et al. STAR/STARD1: a mitochondrial intermembrane space cholesterol shuttle degraded through mitophagy. Proc Natl Acad Sci U S A 2025. 122 e2508809122. ( 10.1073/pnas.2508809122) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.McEnery MW, Snowman AM, Trifiletti RR, et al. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci U S A 1992. 89 3170–3174. ( 10.1073/pnas.89.8.3170) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Šileikytė J, Blachly-Dyson E, Sewell R, et al. Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (translocator protein of 18 kDa (TSPO)). J Biol Chem 2014. 289 13769–13781. ( 10.1074/jbc.m114.549634) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Selvaraj V & Stocco DM. The changing landscape in translocator protein (TSPO) function. Trends Endocrinol Metab 2015. 26 341–348. ( 10.1016/j.tem.2015.02.007) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Gavish M & Veenman L. Regulation of mitochondrial, cellular, and organismal functions by TSPO. Adv Pharmacol 2018. 82 103–136. ( 10.1016/bs.apha.2017.09.004) [DOI] [PubMed] [Google Scholar]
- 14.Bréhat J, Issop L & Morin D. History of Tspo deletion and induction in vivo: phenotypic outcomes under physiological and pathological situations. Biochimie 2024. 224 80–90. ( 10.1016/j.biochi.2024.03.001) [DOI] [PubMed] [Google Scholar]
- 15.Jimenez IA, Stilin AP, Morohaku K, et al. Mitochondrial translocator protein deficiency exacerbates pathology in acute experimental ulcerative colitis. Front Physiol 2022. 13 896951. ( 10.3389/fphys.2022.896951) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Galiègue S, Casellas P, Kramar A, et al. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res 2004. 10 2058–2064. ( 10.1158/1078-0432.ccr-03-0988) [DOI] [PubMed] [Google Scholar]
- 17.Vlodavsky E & Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neuro Oncol 2007. 81 1–7. ( 10.1007/s11060-006-9199-9) [DOI] [PubMed] [Google Scholar]
- 18.Thompson MM, Manning HC & Ellacott KL. Translocator protein 18 kDa (TSPO) is regulated in white and brown adipose tissue by obesity. PLoS One 2013. 8 e79980. ( 10.1371/journal.pone.0079980) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Singh P, Adhikari A, Singh D, et al. The 18-kDa translocator protein PET tracers as a diagnostic marker for neuroinflammation: development and current standing. ACS Omega 2022. 7 14412–14429. ( 10.1021/acsomega.2c00588) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mirzaei N, Tang SP, Ashworth S, et al. In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer’s disease. Glia 2016. 64 993–1006. ( 10.1002/glia.22978) [DOI] [PubMed] [Google Scholar]
- 21.Loth MK, Guariglia SR, Re DB, et al. A novel interaction of translocator protein 18 kDa (TSPO) with NADPH oxidase in Microglia. Mol Neurobiol 2020. 57 4467–4487. ( 10.1007/s12035-020-02042-w) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Corsi F, Baglini E, Barresi E, et al. Targeting TSPO reduces inflammation and apoptosis in an in vitro photoreceptor-like model of retinal degeneration. ACS Chem Neurosci 2022. 13 3188–3197. ( 10.1021/acschemneuro.2c00582) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Liu GJ, Middleton RJ, Kam WWY, et al. Functional gains in energy and cell metabolism after TSPO gene insertion. Cell Cycle 2017. 16 436–447. ( 10.1080/15384101.2017.1281477) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Tu LN, Zhao AH, Hussein M, et al. Translocator protein (TSPO) affects mitochondrial fatty acid oxidation in steroidogenic cells. Endocrinology 2016. 157 1110–1121. ( 10.1210/en.2015-1795) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015. 347 1260419. ( 10.1126/science.1260419) [DOI] [PubMed] [Google Scholar]
- 26.Koganti PP & Selvaraj V. Lack of adrenal TSPO/PBR expression in hamsters reinforces correlation to triglyceride metabolism. J Endocrinol 2020. 247 1–10. ( 10.1530/JOE-20-0189) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hartimath SV, Khanapur S, Boominathan R, et al. Imaging adipose tissue browning using the TSPO-18kDa tracer [18F]FEPPA. Mol Metab 2019. 25 154–158. ( 10.1016/j.molmet.2019.05.003) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kim S, Kim N, Park S, et al. Tanycytic TSPO inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. Autophagy 2019. 16 1200–1220. ( 10.1080/15548627.2019.1659616) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Gut P, Baeza-Raja B, Andersson O, et al. Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat Chem Biol 2013. 9 97–104. ( 10.1038/nchembio.1136) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Leduc MS, Hageman RS, Verdugo RA, et al. Integration of QTL and bioinformatic tools to identify candidate genes for triglycerides in mice. J Lipid Res 2011. 52 1672–1682. ( 10.1194/jlr.M011130) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wade FM, Wakade C, Mahesh VB, et al. Differential expression of the peripheral benzodiazepine receptor and gremlin during adipogenesis. Obes Res 2005. 13 818–822. ( 10.1038/oby.2005.93) [DOI] [PubMed] [Google Scholar]
- 32.Zhao AH, Tu LN, Mukai C, et al. Mitochondrial translocator protein (TSPO) function is not essential for heme biosynthesis. J Biol Chem 2016. 291 1591–1603. ( 10.1074/jbc.M115.686360) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Morohaku K, Phuong NS & Selvaraj V. Developmental expression of translocator protein/peripheral benzodiazepine receptor in reproductive tissues. PLoS One 2013. 8 e74509. ( 10.1371/journal.pone.0074509) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hausman DB, Park HJ & Hausman GJ. Isolation and culture of preadipocytes from rodent white adipose tissue. Methods Mol Biol 2008. 456 201–219. ( 10.1007/978-1-59745-245-8_15) [DOI] [PubMed] [Google Scholar]
- 35.Koganti PP, Tu LN & Selvaraj V. Functional metabolite reserves and lipid homeostasis revealed by the MA-10 Leydig cell metabolome. PNAS Nexus 2022. 1 pgac215. ( 10.1093/pnasnexus/pgac215) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Livak KJ & Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001. 25 402–408. ( 10.1006/meth.2001.1262) [DOI] [PubMed] [Google Scholar]
- 37.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970. 227 680–685. ( 10.1038/227680a0) [DOI] [PubMed] [Google Scholar]
- 38.Tu LN, Showalter MR, Cajka T, et al. Metabolomic characteristics of cholesterol-induced Non-obese nonalcoholic fatty liver disease in mice. Sci Rep 2017. 7 6120. ( 10.1038/s41598-017-05040-6) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Tu LN, Zhao AH, Stocco DM, et al. PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). Endocrinology 2015. 156 1033–1039. ( 10.1210/en.2014-1707) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Morrissey NA, Beall C & Ellacott KLJ. Absence of the mitochondrial translocator protein 18 kDa in mice does not affect body weight or food intake responses to altered energy availability. J Neuroendocrinol 2021. 33 e13027. ( 10.1111/jne.13027) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Verma A, Nye JS & Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci U S A 1987. 84 2256–2260. ( 10.1073/pnas.84.8.2256) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Hunter GA & Ferreira GC. 5-Aminolevulinate synthase: catalysis of the first step in heme biosynthesis. Cell Mol Biol 2009. 55 102–110. [PMC free article] [PubMed] [Google Scholar]
- 43.Lecerof D, Fodje M, Hansson A, et al. Structural and mechanistic basis of porphyrin metallation by ferrochelatase1. J Mol Biol 2000. 297 221–232. ( 10.1006/jmbi.2000.3569) [DOI] [PubMed] [Google Scholar]
- 44.Wendler G, Lindemann P, Lacapere JJ, et al. Protoporphyrin IX binding and transport by recombinant mouse PBR. Biochem Biophys Res Commun 2003. 311 847–852. ( 10.1016/j.bbrc.2003.10.070) [DOI] [PubMed] [Google Scholar]
- 45.Vanhee C, Zapotoczny G, Masquelier D, et al. The Arabidopsis multistress regulator TSPO is a heme binding membrane protein and a potential scavenger of porphyrins via an autophagy-dependent degradation mechanism. Plant Cell 2011. 23 785–805. ( 10.1105/tpc.110.081570) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Busch AWU, WareJoncas Z & Montgomery BL. Tryptophan-rich sensory protein/translocator protein (TSPO) from cyanobacterium fremyella diplosiphon binds a broad range of functionally relevant tetrapyrroles. Biochemistry 2017. 56 73–84. ( 10.1021/acs.biochem.6b01019) [DOI] [PubMed] [Google Scholar]
- 47.do Rego JL, Vaudry D & Vaudry H. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One 2015. 10 e0120473. ( 10.1371/journal.pone.0120473) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Anholt RR, De Souza EB, Oster-Granite ML, et al. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther 1985. 233 517–526. ( 10.1016/s0022-3565(25)21237-x) [DOI] [PubMed] [Google Scholar]
- 49.Costa B, Cavallini C, Da Pozzo E, et al. The anxiolytic etifoxine binds to TSPO Ro5-4864 binding site with long residence time showing a high neurosteroidogenic activity. ACS Chem Neurosci 2017. 8 1448–1454. ( 10.1021/acschemneuro.7b00027) [DOI] [PubMed] [Google Scholar]
- 50.Boissier JR, Simon P, Zaczinska M, et al. [Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine]. Therapie 1972. 27 325–338. [PubMed] [Google Scholar]
- 51.Fonia O, Weizman R, Coleman R, et al. PK 11195 aggravates 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced hepatic porphyria in rats. Hepatol Baltim Md 1996. 24 697–701. ( 10.1053/jhep.1996.v24.pm0008781345) [DOI] [PubMed] [Google Scholar]
- 52.Jaremko L, Jaremko M, Giller K, et al. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 2014. 343 1363–1366. ( 10.1126/science.1248725) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Milenkovic VM, Slim D, Bader S, et al. CRISPR-cas9 mediated TSPO gene knockout alters respiration and cellular metabolism in human primary microglia cells. Int J Mol Sci 2019. 20 3359. ( 10.3390/ijms20133359) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Taylor JMW, Allen AM & Graham A. Targeting mitochondrial 18 kDa translocator protein (TSPO) regulates macrophage cholesterol efflux and lipid phenotype. Clin Sci 2014. 127 603–613. ( 10.1042/CS20140047) [DOI] [PubMed] [Google Scholar]
- 55.Alamri A, Biswas L, Watson DG, et al. Deletion of TSPO resulted in change of metabolomic profile in retinal pigment epithelial cells. Int J Mol Sci 2019. 20 1387. ( 10.3390/ijms20061387) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Yeh P-S, Li C-C, Lu Y-S, et al. Structural insights into the binding and degradation mechanisms of protoporphyrin IX by the translocator protein TSPO. JACS Au 2023. 3 2918–2929. ( 10.1021/jacsau.3c00514) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Ginter C, Kiburu I & Boudker O. Chemical catalysis by the translocator protein (18 kDa). Biochemistry 2013. 52 3609–3611. ( 10.1021/bi400364z) [DOI] [PubMed] [Google Scholar]
- 58.Qiu W, Trinh TKH, Catalano C, et al. Cholesterol-dependent enzyme activity of human TSPO1. Proc Natl Acad Sci U S A 2025. 122 e2323045122. ( 10.1073/pnas.2323045122) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Zeno S, Veenman L, Katz Y, et al. The 18 kDa mitochondrial translocator protein (TSPO) prevents accumulation of protoporphyrin IX. Involvement of reactive oxygen species (ROS). Curr Mol Med 2012. 12 494–501. ( 10.2174/1566524011207040494) [DOI] [PubMed] [Google Scholar]
- 60.Rosenberg N, Rosenberg O, Weizman A, et al. In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein. J Bioenerg Biomembr 2013. 45 333–341. ( 10.1007/s10863-013-9501-4) [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data supporting the findings of this study are available within the article and its Supplementary materials.

This work is licensed under a